Trial Profile
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs OPK 88004 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms SARM-PC
- 12 May 2021 Results assessing safety and efficacy of OPK-88004 in symptomatic, testosterone-deficient men who had undergone radical prostatectomy for low grade, organ-confined prostate cancer, published in the Journal of Clinical Endocrinology and Metabolism.
- 04 Mar 2020 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2019.